Mark G. Kris, M.D., is Chief of the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, at Memorial Sloan-Kettering Cancer Center and Attending Physician at Memorial Hospital for Cancer and Allied Diseases, New York, New York. He is Professor of Medicine at the Weill Medical College of Cornell University and serves as Co-Leader of Memorial Sloan-Kettering's Multidisciplinary Thoracic Disease Management Team. He is the first incumbent of the William and Joy Ruane Chair in Thoracic Oncology.

After receiving his medical degree from the Weill Medical College of Cornell University, he served as Chief Medical Resident and Fellow in Medical Oncology at Memorial Sloan-Kettering Cancer Center.

He is author or coauthor of 200 original scientific publications. Dr. Kris holds memberships in the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer. He is a member of the guideline panels on non-small cell lung cancer and antiemesis for the National Comprehensive Cancer Network. He serves as co-chair of the American Society of Clinical Oncology guideline panel for adjuvant chemotherapy and radiation for non-small cell lung cancer. He headed the Antiemetic Guideline Panel for the 2006 update for the American Society of Clinical Oncology. In addition, he is a Fellow of the American College of Physicians and the American College of Chest Physicians. Dr. Kris serves on the Medical Advisory Board of Cancer Care, Inc. and The Joan's Legacy Foundation. He is the Thoracic section editor of cancer.net.

Dr. Kris is a specialist in lung cancer, thymoma, and neuroendocrine tumors arising in the chest. His research includes the evaluation of new anticancer agents (particularly those targeting lung cancer), multimodality therapy (using surgery, radiation, and medications together to improve outcomes for individuals with thoracic cancers), and the testing of drugs to prevent nausea and emesis. He is particularly interested in developing strategies to choose treatments for patients based on molecular characteristics of their tumor specimens.

Disclosure:

Has served as a consultant for AstraZeneca, Bristol-Myers Squibb, ImClone, and Pfizer

Has served as a speaker for Sanofi-Aventis